Hemispherx Biopharma Updates Chronic Fatigue Syndrome (CFS) Treatment
November 02, 2009 9:48 AM
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced a two-prong CFS clinical mission for November and December 2009.
Hemispherx Biopharma plans to widen its ongoing clinical programs in CFS by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome (please see October 8, 2009, online issue of Science). A clinically validated test to detect retrovirus antibodies in patients plasma is also currently under development (please see US National Institutes of Health at: http://www.cancer.gov/newscenter/pressreleases/CFSxmrv). With the consortium of researchers at the Whittemore Peterson Institute, the Company is also now evaluating the defect in immunosurveillance in specific subsets of CFS patients in a clinical study entitled "Therapeutic Activation of NK lymphocytes to Alleviate Chronic Fatigue Syndrome." These immune defects may be due to the previously undetected retrovirus.
